title: Sulfasalazine has a better efficacy/toxicity profile than auranofin--evidence from a 5 year prospective, randomized trial.
abstract: OBJECTIVE
  To compare results of medium to longterm sulfasalazine and auranofin treatment in active rheumatoid arthritis (RA).
  
  
  METHODS
  200 patients with active RA were enrolled in a prospective, randomized trial comparing sulfasalazine (target dosage, 40 mg/kg/day) with auranofin (6-9 mg/day). Patients were assessed annually for 5 years, using clinical and laboratory measures of disease activity. Risk of discontinuing treatment was compared using life table analysis.
  
  
  RESULTS
  31% of patients continued sulfasalazine for at least 5 years, compared to only 15% continuing auranofin (p < 0.05). Patients previously given intramuscular (i.m.) gold did particularly badly during auranofin treatment (only 1/26 continued therapy for 5 years), but after excluding all patients previously treated with i.m. gold from both groups more patients continued sulfasalazine for > 5 years (p < 0.05). Patients continuing therapy at 5 years had significantly milder disease at enrollment than those who did not. The patients continuing auranofin treatment at 5 years were no better than at the outset of the trial, and may represent a subgroup of patients with a good prognosis. Patients continuing sulfasalazine, however, showed sustained response over the 5 year period.
  
  
  CONCLUSIONS
  Sulfasalazine therapy was more likely to be continued for 5 years, suggesting better tolerability and/or efficacy than auranofin, and produced evidence of continuing benefit. Patients previously withdrawn from i.m. gold therapy because of inefficacy or minor toxicity should not be given auranofin therapy.
authors.affiliation: Centre for Rheumatic Diseases, Glasgow Royal Infirmary, UK.
authors.forename: A
authors.initials: A
authors.lastname: McEntegart
authors.forename: D
authors.initials: D
authors.lastname: Porter
authors.forename: H A
authors.initials: HA
authors.lastname: Capell
authors.forename: E A
authors.initials: EA
authors.lastname: Thomson
mesh_terms: D018501:Antirheumatic Agents / Q000494:pharmacology*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy*; D001310:Auranofin / Q000494:pharmacology*; D001799:Blood Sedimentation / Q000187:drug effects; D002097:C-Reactive Protein / Q000187:drug effects; D003710:Demography; D004548:Elasticity / Q000187:drug effects; D005260:Female; D006801:Humans; D007596:Joints / Q000187:drug effects; D008297:Male; D008875:Middle Aged; D010147:Pain Measurement / Q000187:drug effects; D012460:Sulfasalazine / Q000494:pharmacology*; D016896:Treatment Outcome
chemical_list: D018501:Antirheumatic Agents; D001310:Auranofin; D012460:Sulfasalazine; D002097:C-Reactive Protein